Stock 2196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Delayed Hong Kong S.E.
Other stock markets
 11:59:51 2024-04-29 pm EDT 		5-day change 1st Jan Change
12.24 HKD -1.13% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +4.08% -28.00%
Apr. 29 Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
Shanghai Fosun Pharmaceutical : Fosun Pharma and Insightec Establish Joint Venture to Expand Global Access to Focused Ultrasound Treatment for Neurological Diseases
PU
Marubeni Corporation - Expansion of Pharmaceutical Business Initiatives
AQ
Fosun Pharma’s 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
PU
Shanghai Fosun Pharmaceutical : COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR
PU
Syneos Health Announces Partnership with Fosun Pharma USA to Launch SerplulimabRelationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions
AQ
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
AQ
Shanghai Fosun Pharmaceutical : Self-Paid Vaccination Service for Bivalent COVID-19 Vaccine COMIRNATY® is Officially Provided in Hong Kong, Offering More Vaccine Options for People in Need
PU
Shanghai Fosun Pharmaceutical : Fosun Pharma Announces Results for the First Three Quarters of 2022
PU
Shanghai Fosun Pharmaceutical : Fosun Pharma’s MSCI ESG Rating Upgraded to A
PU
Neovii and Fosun Pharma Enter into an Exclusive Agreement
AQ
Shanghai Fosun Pharmaceutical : Fosun Pharma Topped the 2022 Fortune China ESG Impact List
PU
Shanghai Fosun Pharmaceutical : Fosun Pharma and Amgen Announce Collaboration to Accelerate Two Innovative Medicines Benefitting Chinese Patients
PU
Shanghai Fosun Pharmaceutical : Continuously Promoting Innovation and Internationalization Fosun Pharma Presents at 2022 BIO International Convention
PU
Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - ENTERING INTO SALE AND PURCHASE AGREEMENTS （H SHARES）
PU
Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022(H SHARES)
PU
Shanghai Fosun Pharmaceutical : (1) RE-APPOINTMENT OF CHAIRMAN AND VICE CHAIRMAN (2) APPOINTMENT OF CO-CHAIRMAN (3) APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND CO-CHIEF EXECUTIVE OFFICER AND (4) CHANGE IN BOARD COMMITTEE COMPOSITION
PU
Shanghai Fosun Pharmaceutical : Axicabtagene Ciloleucel - Fosun Kite's CAR-T Cell Therapy Approved to be Included in the 2022 Version of Shanghai “Huhuibao”
PU
Shanghai Fosun Pharmaceutical : Fosun Pharma and VerImmune enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China
PU
Shanghai Fosun Pharmaceutical : NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS (H SHARES)
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 2196 Stock
  5. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Press Releases